CRIS Current Research Information System

MARTELLO, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.593
NA - Nord America 3.051
EU - Europa 2.202
AF - Africa 251
SA - Sud America 183
OC - Oceania 3
Totale 9.283
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.980
VN - Vietnam 1.121
CN - Cina 861
SG - Singapore 836
IT - Italia 771
GB - Regno Unito 301
DE - Germania 243
HK - Hong Kong 214
SE - Svezia 189
IN - India 151
NL - Olanda 136
BR - Brasile 130
FR - Francia 130
KR - Corea 115
RU - Federazione Russa 88
CI - Costa d'Avorio 86
BD - Bangladesh 79
IE - Irlanda 72
FI - Finlandia 55
JP - Giappone 45
SC - Seychelles 43
TG - Togo 41
ZA - Sudafrica 37
CA - Canada 36
PH - Filippine 32
CH - Svizzera 29
BG - Bulgaria 28
AT - Austria 27
AR - Argentina 26
UA - Ucraina 25
NG - Nigeria 23
MX - Messico 22
PL - Polonia 22
EE - Estonia 20
TH - Thailandia 19
ES - Italia 18
ID - Indonesia 18
BE - Belgio 17
TW - Taiwan 14
JO - Giordania 12
IQ - Iraq 11
TR - Turchia 11
IR - Iran 10
EC - Ecuador 9
SA - Arabia Saudita 8
RO - Romania 7
CO - Colombia 6
DZ - Algeria 5
CL - Cile 4
CY - Cipro 4
CZ - Repubblica Ceca 4
GR - Grecia 4
GT - Guatemala 4
PK - Pakistan 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
HR - Croazia 3
LT - Lituania 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
UZ - Uzbekistan 3
VE - Venezuela 3
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
EG - Egitto 2
GE - Georgia 2
IL - Israele 2
JM - Giamaica 2
KE - Kenya 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
PS - Palestinian Territory 2
RS - Serbia 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AL - Albania 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LU - Lussemburgo 1
MA - Marocco 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PY - Paraguay 1
QA - Qatar 1
TZ - Tanzania 1
ZW - Zimbabwe 1
Totale 9.283
Salva come PNG Salva come JPEG
Città #
Singapore 579
Ashburn 392
Ho Chi Minh City 311
Chandler 275
Southend 243
Hanoi 240
Hefei 240
Hong Kong 209
Dallas 204
Fairfield 188
San Jose 184
Bologna 179
Ann Arbor 121
Seoul 108
Beijing 99
New York 88
Abidjan 86
Houston 83
Wilmington 78
Woodbridge 78
Dublin 72
Seattle 70
Cambridge 67
Princeton 66
Milan 62
Los Angeles 61
Santa Clara 55
Lauterbourg 53
Boardman 51
Haiphong 44
Helsinki 43
Lomé 41
Hyderabad 39
Dong Ket 38
Tokyo 37
Munich 36
Bremen 31
Nanjing 31
Da Nang 27
Fabriano 27
Rome 27
Sofia 27
Frankfurt am Main 26
São Paulo 25
Amsterdam 24
Buffalo 24
Council Bluffs 24
Turin 23
Westminster 23
Bengaluru 22
Abeokuta 20
Berlin 20
Padova 20
Salsomaggiore Terme 20
Vienna 20
Guangzhou 18
Redmond 18
Biên Hòa 17
Can Tho 17
Bern 16
Brussels 16
Toronto 16
Warsaw 16
Ha Long 15
Redondo Beach 15
Medford 14
Quận Bình Thạnh 14
Shenyang 14
Nuremberg 13
Shanghai 13
Thái Nguyên 13
Amman 12
Florence 12
Hải Dương 12
London 12
Naples 12
Ninh Bình 12
Redwood City 12
Saint Petersburg 12
Wuhan 12
Changsha 11
Falkenstein 11
Jakarta 11
Jinan 11
Tianjin 11
Johannesburg 10
Nanchang 10
Orem 10
Quận Một 10
Lappeenranta 9
Modena 9
Mondolfo 9
Zhengzhou 9
Bắc Ninh 8
Bến Tre 8
Chicago 8
Dhaka 8
Orlando 8
Paris 8
Brooklyn 7
Totale 5.820
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 711
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 320
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 235
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 230
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 229
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 222
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 215
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 211
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 210
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 209
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 205
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 204
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 203
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 202
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 199
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 198
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 197
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 189
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 184
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 178
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 177
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 174
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 174
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 174
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 171
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 168
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 166
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 166
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 163
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 156
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 155
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 155
A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies 154
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 153
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 153
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 150
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 141
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 141
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 139
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 135
Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts 132
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 132
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 131
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma 125
COMPARISON BETWEEN NGS IGH/TCR AND RT-PCR BCR::ABL1 MINIMAL RESIDUAL DISEASE IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY ANALYSIS 111
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 109
null 98
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 92
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 87
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 85
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 79
Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma 68
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives 61
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application 38
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? 37
Totale 9.455
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202186 0 0 0 0 0 0 0 0 0 0 0 86
2021/2022794 73 41 37 62 62 41 27 50 40 99 120 142
2022/20231.073 96 140 47 170 81 80 29 57 157 48 84 84
2023/2024486 39 46 43 39 31 97 26 88 14 19 24 20
2024/20251.363 98 132 112 110 121 61 111 57 30 156 126 249
2025/20264.473 356 963 350 319 367 174 361 166 803 258 220 136
Totale 9.455